Alkermes plc. revenue by segment ALKS

Annual Quarterly

Alkermes plc. splits its revenue into 7 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Vivitrol at $127.6 million, 27% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Revenue	1,754	480	496	393	385	394	391	307	430
Vivitrol	—	128 +5.3% share 26.6%	124 +2.3% share 25.1%	112 +11.3% share 28.6%	124 -7.5% share 32.3%	121 share 30.7%	122 share 31.1%	101 share 33.0%	134 share 31.2%
Aristada And Aristada Initio	—	104 +6.0% share 21.6%	97 share 19.5%	—	—	98 share 24.9%	—	73 share 24.0%	97 share 22.5%
LYBALVI	—	96 -2.4% share 20.0%	94 +11.5% share 18.9%	92 +31.9% share 23.5%	94 +22.3% share 24.5%	98 share 24.9%	84 share 21.6%	70 share 22.8%	77 share 17.9%
LUMRYZ	—	90 share 18.7%	97 share 19.5%	39 share 10.1%	—	—	—	—	—
Manufactured Product And Royalty	—	63 -18.1% share 13.1%	84 +1.0% share 17.0%	55 -11.6% share 13.9%	69 -43.5% share 18.0%	77 share 19.5%	83 share 21.4%	62 share 20.2%	122 share 28.4%
Research And Development	—	—	—	—	—	—	—	—	0 share 0.0%
Manufacturing Revenue	—	-0 -103.5% share -0.1%	21 +26.2% share 4.2%	4 -76.5% share 1.0%	3 -93.8% share 0.9%	9 share 2.2%	17 share 4.2%	17 share 5.7%	53 share 12.4%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: ALKS (Nasdaq)
Fiscal year ends: December 31
Headquarters: Dublin 4, Ireland
SEC filer status: Large accelerated filer
SEC CIK: 1520262
Former names: ANTLER SCIENCE TWO PLC (until Aug 5, 2011); Antler Science Two Ltd (until Aug 2, 2011)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.